family with sequence similarity 86 member H, pseudogeneGenealiases: []
Q-omics provides the consensus-scored FAM86HP profile across patient tissues and cancer cell-line models. FAM86HP expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, FAM86HP is differentially expressed in 12, with the highest sampling consensus in COAD. Additionally, FAM86HP RNA expression shows 19,629 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight UVM, COAD, and ACC as cancer lineages where FAM86HP shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FAM86HP — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FAM86HP survival associations across molecular data types. FAM86HP RNA expression shows survival associations in the most cancer types (21), followed by mutation status (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FAM86HP RNA expression–survival associations across cancer types. High FAM86HP expression shows unfavorable associations in KIRC, ACC, LGG and SKCM, but favorable associations in UVM and HNSC. The UVM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for FAM86HP RNA expression.
This table summarizes FAM86HP tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for FAM86HP. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FAM86HP shows lower tumor expression in KICH and higher tumor expression in COAD, HNSC, LUAD, LUSC and LIHC. The COAD box plot shows higher FAM86HP RNA expression in tumor versus normal tissue (log2 FC = +0.810, t-test p < 0.001).
This table shows molecular features associated with FAM86HP in patient tissues and cancer cell lines. In patient samples, FAM86HP shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set.
